Los Angeles Capital Management & Equity Research Inc. purchased a new position in HeartWare International Inc. (NASDAQ:HTWR) during the second quarter, Holdings Channel reports. The fund purchased 7,425 shares of the company’s stock, valued at approximately $429,000.
Several other large investors have also recently added to or reduced their stakes in HTWR. Legal & General Group Plc raised its stake in HeartWare International by 6.1% in the first quarter. Legal & General Group Plc now owns 3,880 shares of the company’s stock worth $121,000 after buying an additional 223 shares during the last quarter. Swiss National Bank raised its stake in HeartWare International by 7.8% in the second quarter. Swiss National Bank now owns 27,800 shares of the company’s stock worth $1,605,000 after buying an additional 2,000 shares during the last quarter. Sphinx Trading LP bought a new stake in HeartWare International during the second quarter worth about $144,000. State Board of Administration of Florida Retirement System raised its stake in HeartWare International by 18.4% in the second quarter. State Board of Administration of Florida Retirement System now owns 17,137 shares of the company’s stock worth $990,000 after buying an additional 2,662 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in HeartWare International by 3.0% in the first quarter. Geode Capital Management LLC now owns 115,683 shares of the company’s stock worth $3,634,000 after buying an additional 3,374 shares during the last quarter.
Shares of HeartWare International Inc. (NASDAQ:HTWR) remained flat at $57.98 during mid-day trading on Friday. The company has a 50 day moving average price of $57.82 and a 200 day moving average price of $39.18. HeartWare International Inc. has a 52-week low of $25.02 and a 52-week high of $87.38.
HeartWare International (NASDAQ:HTWR) last announced its quarterly earnings data on Thursday, July 28th. The company reported ($0.43) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.82) by $0.39. The business earned $68.72 million during the quarter, compared to analyst estimates of $57.36 million. During the same quarter in the prior year, the company earned ($0.47) earnings per share. The company’s quarterly revenue was down 6.6% on a year-over-year basis. Analysts anticipate that HeartWare International Inc. will post ($3.07) earnings per share for the current year.
HTWR has been the topic of a number of recent research reports. Zacks Investment Research raised HeartWare International from a “hold” rating to a “buy” rating and set a $65.00 target price on the stock in a research note on Tuesday, August 2nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $58.00 target price on shares of HeartWare International in a research note on Thursday, July 28th. Barclays PLC lowered HeartWare International from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $35.00 to $58.00 in a research note on Wednesday, June 29th. BTIG Research reissued a “hold” rating on shares of HeartWare International in a research note on Thursday, August 25th. Finally, Wells Fargo & Co. lowered HeartWare International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 29th. Fourteen research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $50.00.
In related news, CFO Peter F. Mcaree sold 3,125 shares of the stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $57.68, for a total value of $180,250.00. Following the transaction, the chief financial officer now directly owns 22,130 shares in the company, valued at $1,276,458.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP James Schuermann sold 1,000 shares of the stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $57.77, for a total transaction of $57,770.00. Following the completion of the transaction, the senior vice president now owns 12,043 shares in the company, valued at $695,724.11. The disclosure for this sale can be found here.
About HeartWare International
Heartware International, Inc is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The Company operates in the segment of design and manufacture of medical devices.
Want to see what other hedge funds are holding HTWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HeartWare International Inc. (NASDAQ:HTWR).
Receive News & Ratings for HeartWare International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartWare International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.